Pulmonology · Medical Literature
Respiratory-Endocrinology Multidisciplinary Co-Management Pathway in Hospitalized Patients with ECOPD and Diabetes: A Randomized Controlled Trial.
Abstract
Exacerbation of chronic obstructive pulmonary disease (ECOPD) frequently coexists with diabetes mellitus, creating competing priorities for respiratory stabilization and safe inpatient glycemic control. Evidence for an integrated, respiratory-endocrinology co-management pathway in this population remains limited. A total of 162 inpatients hospitalized with ECOPD and comorbid diabetes between January 1 and December 31, 2025 were randomly allocated to a respiratory-endocrinology multidisciplinary co-management pathway or usual care. The intervention comprised an ECOPD care bundle, protocolized glycemic management, pulmonary rehabilitation, and a structured discharge transition package. Primary outcomes were chronic airways assessment test (CAAT) and patient-day hyperglycemia/hypoglycemia. Secondary outcomes included length of stay, 30-day readmission, functional capacity assessed by the 1-min sit-to-stand (1-min STS) test (at discharge and 30 days), patient satisfaction (CSQ-8; at discharge and 30 days), and care-transition quality measured by the Care Transitions Measure-3 (CTM-3; at 7 and 30 days). Compared with usual care, co-management yielded clinically meaningful improvements in CAAT at discharge and at 30 days. Co-management reduced hyperglycemic patient-days (rate ratio 0.799) without an increase in mild, moderate or severe hypoglycemia. The intervention group also had a shorter length of stay, a lower 30-day readmission rate, higher CSQ-8 scores, higher CTM-3 scores, and greater 1-min sit-to-stand performance at discharge and 30 days. Findings were consistent in sensitivity analyses restricted to systemic corticosteroid recipients. A structured respiratory-endocrinology multidisciplinary co-management pathway improved ECOPD-related health status and inpatient glycemic safety while enhancing functional recovery, patient experience, and short-term utilization outcomes in hospitalized patients with ECOPD and diabetes.
Clinical relevance
In hospitalized patients with acute exacerbation of COPD (ECOPD) and comorbid diabetes mellitus, does a structured respiratory–endocrinology multidisciplinary co-management pathway improve COPD-related health status and inpatient glycemic safety compared with usual care? __SNAPSHOT__ {"studyDesign":"Randomized controlled trial (RCT)","setting":"Inpatient hospital setting; country and institution type not reported in abstract","sampleSize":"n=162 (intervention: not reported, control: not reported; allocation ratio not reported in abstract)","population":"Adult inpatients hospitalized with ECOPD and comorbid diabetes mellitus; additional inclusion/exclusion criteria not reported in abstract","intervention":"Respiratory–endocrinology multidisciplinary co-management pathway comprising: an ECOPD care bundle, protocolized glycemic management, inpatient pulmonary rehabilitation, and a structured discharge transition package","comparator":"Usual care (parallel-specialty standard inpatient management; specific components not defined in abstract)","primaryOutcome":"Chronic Airways Assessment Test (CAAT) score (0–40; higher = worse health status) at discharge and 30 days post-discharge; AND inpatient glycemic safety measured by patient-day hyperglycemia (mean daily blood glucose >180 mg/dL) and hypoglycemia (mild ≤70, moderate <54, severe ≤40 mg/dL)","followUp":"30 days post-discharge (with additional CTM-3 assessment at 7 days post-discharge)","fundingSource":"Not reported"}
Key findings
Compared with usual care, the co-management pathway yielded clinically meaningful improvements in CAAT scores at both the discharge and 30-day post-discharge time points; exact mean score differences, confidence intervals, and p-values are not reported in the abstract. For the glycemic primary outcome, co-management reduced hyperglycemic patient-days (rate ratio 0.799; 95% CI and p-value not reported in abstract) without an increase in mild, moderate, or severe hypoglycemia. A rate ratio of 0.799 corresponds to approximately a 20.1% relative reduction in hyperglycemic patient-days (calculated). Absolute reduction in hyperglycemic patient-days and NNT cannot be calculated from the available data. All prespecified secondary outcomes also favored the intervention: shorter length of stay, lower 30-day readmission rate, higher patient satisfaction (CSQ-8) at discharge and 30 days, higher care-transition quality (CTM-3) at 7 and 30 days, and greater 1-minute sit-to-stand test performance at discharge and 30 days. Specific values, effect sizes, and p-values for all secondary outcomes are not reported in the abstract. Results were consistent in a pre-specified sensitivity analysis restricted to patients receiving systemic corticosteroids.
Practice implications
This RCT provides preliminary randomized evidence that a structured respiratory–endocrinology co-management pathway can simultaneously address COPD health status and inpatient glycemic safety in the clinically challenging intersection of ECOPD and diabetes—a population typically managed through siloed specialty workflows. The finding of reduced hyperglycemic patient-days without increased hypoglycemia is clinically meaningful given the known association of both hyper- and hypoglycemia with adverse inpatient outcomes. The consistency of benefit across respiratory, glycemic, functional, patient-experience, and utilization outcomes is notable and, if confirmed, would support the clinical value of integrated care models. However, several key limitations prevent practice change at this time: the abstract does not report exact effect sizes, confidence intervals, or p-values for CAAT improvements or any secondary endpoint; the clinical magnitude of CAAT change relative to established minimum clinically important difference (MCID) thresholds cannot be verified from available data; blinding, allocation concealment, and randomization procedures are not described; and the single-year enrollment window and single-site (or limited-site) design raise concerns about external validity. The population is well-defined (ECOPD + diabetes), but subgroup data by COPD severity, diabetes type, insulin use, and comorbidity burden are not reported. Only the abstract is available for this review, which substantially limits appraisal of methodological rigor. __LIMITATIONS__ Only the abstract is publicly available; full methods, complete results tables, confidence intervals, and p-values for most outcomes cannot be independently verified.,Exact CAAT score differences and comparison to established MCID (≥2 points for CAT/CAAT) are not reported, preventing definitive determination of clinical importance.,Blinding: patient and clinician blinding is not feasible for a complex care pathway RCT; assessor blinding status is not reported.,Allocation concealment and randomization method are not described in the abstract.,Relatively small sample (n=162); underpowered for rare outcomes such as severe hypoglycemia or mortality.,Single-year enrollment (January–December 2025) may reflect seasonal or institutional case-mix variation.,Institutional setting and country not reported, limiting generalizability to other healthcare systems.,Usual care comparator is not operationally defined, making the magnitude of the 'co-management' effect dependent on baseline usual care quality.,Follow-up limited to 30 days; longer-term durability of glycemic control, functional gains, and readmission reduction is unknown.,No mortality data reported.,Funding source not disclosed; potential conflicts of interest cannot be assessed.,Subgroup analyses by diabetes type, insulin use, COPD severity (GOLD stage), and corticosteroid dose are not reported beyond the corticosteroid-recipient sensitivity analysis. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This single-year RCT (n=162) suggests that a respiratory–endocrinology multidisciplinary co-management pathway reduces hyperglycemic patient-days (rate ratio 0.799; ~20% relative reduction [calculated]) and improves COPD health status, functional capacity, and 30-day readmission in hospitalized patients with ECOPD and diabetes, without increasing hypoglycemia. However, key statistical parameters, confidence intervals, and methodological details are not reported in the available abstract, precluding definitive appraisal of effect size and trial quality. Replication in multicenter settings with full methodological transparency and longer follow-up is needed before this pathway is adopted as standard practice.